Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents

Journal of Medicinal Chemistry

Volumn 54, Issue 11, 2011, Pages 3686-3703

  Hossion, Abugafar M L ^a   Zamami, Yoshito ^a   Kandahary, Rafiya K ^a   Tsuchiya, Tomofusa ^b   Ogawa, Wakano ^b   Iwado, Akimasa ^a   Sasaki, Kenji ^a  

^a Department of Molecular Design for Medicine ^*  (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3',4' DIHYDROXYPHENYL) 5,7 DIHYDROXY 3 BETA DEXTRO [2'',6'' DI O [3''' (4 FLUOROPHENYLPROPANOYL)]]GALACTOSYL 4H CHROMEN 4 ONE; 3,7 DIACYLQUERCETIN; BACTERIAL ENZYME; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; NORFLOXACIN; NOVOBIOCIN; QUERCETIN; QUERCETIN 2'',6'' DIACYLGALACTOSIDE; QUERCETIN 6'' ACYLGALACTOSIDE; QUERCETIN DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ABSORPTION; DRUG POTENCY; ENZYME INHIBITION; ESCHERICHIA COLI; INTESTINE ABSORPTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; RAT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STRUCTURE ACTIVITY RELATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG DESIGN; ENZYME INHIBITORS; GALACTOSIDES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; QUERCETIN; RATS; RATS, WISTAR;

EID: 79958140054     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200010x     Document Type: Article

References (61)

1. Center for disease control and prevention, public health dispatch: Vancomycin-resistant Staphylococcus aureus-Pennsylvania. MMWR Morb. Mortal. Wkly. Rep. 2002, 51, 902-902.
2. Levy, S. B.; Marshall, B. Antibacterial resistance worldwide: Cause, challenges and responses. Nat. Med. 2004, 10, S122-S129. (Pubitemid 40018235)
3. Aspa, J.; Rajas, O.; Rodriguez de Castro, F.; Blanquer, J.; Zalacain, R.; Fenoll, A.; de Celis, R.; Vargas, A.; Salvanes, F. R.; Espana, P. P.; Rello, J.; Torres, A. Drug-resistant pneumococcal pneumonia: Clinical relevance and related factors. Clin. Infect. Dis. 2004, 38, 787-798. (Pubitemid 38387224)
4. Barrett, C. T.; Barrett, J. F. Antibacterials: Are the new entries enough to deal with the emerging resistance problems?. Curr. Opin. Biotechnol. 2003, 14, 621-626. (Pubitemid 37518441)
5. Livermore, D. M. The need for new antibiotics. Clin. Microbial. Infect. 2004, 10 (Suppl. 4), 1-9.
6. Jacobs, M. R. Worlwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr. Infect. Dis. J. 2003, 22, S109-S119. (Pubitemid 36999638)
7. Häbich, D.; von Nussbaum, F. Platensimycin, a new antibiotic and "superbug challenger" from nature. ChemMedChem 2006, 1, 951-954. (Pubitemid 44448792)
8. Thomson, C. J.; Power, E.; Ruebsamen-Waigmann, H.; Labischinski, H. Antibacterial research and development in the 21(st) century-an industry perspective of the challenges. Curr. Opin. Microbiol. 2004, 7, 445-450. (Pubitemid 39297123)
9. Mutnick, A. H.; Enne, V.; Jones, R. N. Linezolid resistance since 2001. SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 2003, 37, 909-911.
10. Hachem, R. Y.; Hicks, K.; Huen, A.; Raad, I. Myelosupperssion and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitora in bone marrow transplant recipients. Clin. Infect. Dis. 2003, 37, e8-e11.
11. Hidron, A. I.; Schuetz, A. N.; Nolte, F. S.; Gould, C. V.; Osborn, M. K. Daptomycin resistance in enterococcus faecalis prosthetic valve endocarditis. Antimicrob. Chemother. 2008, 61, 1394-1396. (Pubitemid 351753616)
12. Maxwell, A. DNA gyrase as a drug target. Trends Microbiol. 1997, 5, 102-109. (Pubitemid 27139470)
13. Maxwell, A.; Lawson, D. M. The ATP binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 2003, 3, 283-303.
14. Drlica, K.; Zhao, X. DNA gyrase, topisomerase IV and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61, 377-392.
15. Heisig, P. Inhibitors of bacterial topoisomerases: Mechanisms of action and resistance and clinical aspects. Planta Med. 2001, 67, 3-12. (Pubitemid 32199937)
16. Ferrero, L.; Cameron, B.; Manse, B.; Lagneaux, D.; Crouzet, J.; Famechon, A.; Blanche, F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones. Mol. Microbiol. 1994, 13, 641-653. (Pubitemid 24266200)
17. Kato, J.-I.; Nishimura, Y.; Imamura, R.; Niki, H.; Hiraga, S.; Suzuki, H. New topoisomerases essential for chromosome segregation in E. coli. Cell 1990, 63, 393-404.
18. Deibler, R. W.; Rahmati, S.; Zechiedrich, E. L. Topoisomerase IV, alone, unknots DNA in E. coli. Genes Dev. 2001, 15, 748-761. (Pubitemid 32244903)
19. Zechiedrich, E. L.; Khodrusky, A. B.; Bachellier, S.; Schneider, R.; Chen, D.; Lilley, D. M. J.; Cozzarelli, N. R. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J. Biol. Chem. 2000, 275, 8103-8113. (Pubitemid 30159724)
20. Chen, A. Y.; Liu, L. F. DNA Topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 191-218.
21. Bellon, S.; Parsons, J. D.; Wei, Y.; Haykawa, K.; Swenson, L. L.; Charifson, P. S.; Lippke, J. A.; Aldape, R.; Gross, C. H. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kDas): A single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. 2004, 48, 1856-1864. (Pubitemid 38544398)
22. Gross, C. H.; Parsons, J. D.; Grossman, T. H.; Charifson, P. S.; Bellon, S.; Jernee, J.; Dwyer, M.; Chambers, S. P.; Markland, W.; Botfield, M.; Raybuck, S. A. Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance. Antimicrob. Agents Chemother. 2003, 47, 1037-1046. (Pubitemid 36254232)
23. Munoz, R.; Bustamante, M.; de la Campa, A. G. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in nivobiocin resistance. J. Bacteriol. 1995, 177, 4166-4170.
24. Booker, B. M.; Smith, P. F.; Forrest, A.; Bullock, J.; Kelchlin, P.; Bhavnani, S. M.; Jones, R. N.; Ambrose, P. G. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica Serotype Typhi. Antimicrob. Agents Chemother. 2005, 49, 1775-1781. (Pubitemid 40631588)
25. Jones, R. N. Should novobiocin be clinically re-evaluated?. Diagn. Microbiol. Infect. Dis. 1989, 12, 363-365. (Pubitemid 20000984)
26. Kaldas, M. I.; Walle, K.; van Der Woude, H.; McMillan, J. M.; Walle, T. Covalent binding to the flavonoid quercetin to human serum albumin. J. Agric. Food. Chem. 2005, 53, 4194-4197. (Pubitemid 40936783)
27. Castillo-Mu~noz, N.; Gómez-Alonso, S.; García-Romero, E.; Gómez, M. V.; Velders, A. H.; Hermosín-Gutiérrez, I. Flavonol 3-Oglycosides series of Vitis vinifera CV. Petit Verdot red wine grapes. J. Agric. Food. Chem. 2009, 57, 209-219.
28. Hossion, A. M. L.; Otsuka, N.; Kandahary, R. K.; Tsuchiya, T.; Ogawa, W.; Iwado, A.; Zamami, Y.; Sasaki, K. Design, synthesis and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents. Bioorg. Med. Chem. Lett. 2010, 20, 5349-5352.
29. Sasaki, K.; Tsuchiya, T.; Hossion, A. M. L. Novel flavanone derivative. PCT Int. Appl. WO 2011013735, 2011; National University Corporation Okayama University: Japan; http://www.sumobrain.com/ patents/wipo/Novel-flavanone- derivative/WO2011013735.html.
30. Bloor, S. J. An antimicrobial kaempferol-diacyl-rhamnoside from Pentachondra pumila. Phytochemistry 1995, 38, 1033-1035.
31. Otsuka, N.; Liu, M.-H.; Shiota, S.; Ogawa, W.; Kuroda, T.; Hatano, T.; Tsuchiya, T. Anti-methicillin resistant Staphylococcus aureus (MRSA) compounds isolated from Laurus nobilis. Biol. Pharm. Bull. 2008, 31, 1794-1797.
32. Liu, M, -H.; Otsuka, N.; Noyori, K.; Shiota, S.; Ogawa, W.; Kuroda, T.; Hatano, T.; Tsuchiya, T. Synergistic effect of kaempferol glycosides purified from Laurus nobilis and fluloroquinolones on methicillin- resistant Staphylococcus aureus. Biol. Pharm. Bull. 2009, 32, 489-492.
33. pro: Structure-activity relationship studies reveal salient pharmacophore features. Bioorg. Med. Chem. 2006, 14, 8295-8306. (Pubitemid 44667555)
34. Neises, B.; Steglich, W. Esterification of carboxylic acids with diacylcyclohexylcarbodiimide/4-dimethylaminopyridine: Tert-Butyl ethyl formate. Organic Syntheses; Wiley & Sons: New York, 1990; Vol. 7, pp 93-93.
35. Bauman, W. C.; Skidmore, J. R.; Osmun, R. H.DOWEX50-A new high capacity cation exchange resisn. Ind. Eng. Chem. 1948, 40, 1350-1355.
36. Clinical and Laboratory Standard Institute (CLSI). Methods for Dilution Antibacterial Susceptibility Test for Bacteria That Grow Aerobically, 7th ed.; Approved Standard (MA7-A7); Clinical and Laboratory Standard Institute: Wayne, 2007; Vol. 27, p 133.
37. Plaper, A.; Golob, M.; Hafner, I.; Oblak, M.; Solmajer, T.; Jerela, R. Characterization of quercetin binding site on DNA gyrase. Biochem. Biophys. Res. Commun. 2003, 306, 530-536. (Pubitemid 36683107)
38. Marcu, M. G.; Chadli, A.; Bouchouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186. (Pubitemid 32002137)
39. Gradišar, H.; Pristovsek, P.; Plaper, A.; Jerala, R. Green tea catechins inhibit bacterial DNA gyrase by interection with its ATP binding site. J. Med. Chem. 2007, 50, 264-271. (Pubitemid 46147707)
40. Levine, C.; Hiasa, H.; Marians, K. J. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosomes replication, and drug sensitivities. Biochim. Biophys. Acta 1998, 1400, 29-43. (Pubitemid 28475094)
41. Gellert, M.; Mizuuchi, K.; O'Dea, M. H.; Nash, H. A. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 3872-3876.
42. Ferrero, L.; Cameron, B.; Crouzet, J. Analysis of gyrA and grlA muatations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 1995, 39, 1554-1558.
43. Yamagishi, J. -I.; Kojima, T.; Oyamada, Y.; Fujimoto, K.; Hattori, H.; Nakamura, S.; Inoue, M. Alternations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 1996, 40, 1157-1163. (Pubitemid 26136027)
44. Rosenfeld, R. J.; Goodsell, D. S.; Musah, R. A.; Morris, G. M.; Goodin, D. B.; Olson, A. J. Automated docking of ligands to an artificial active site: Augmenting crystallographic analysis with computer modeling. J. Comput.-Aided Mol. Des. 2003, 17, 525-536. (Pubitemid 38008964)
45. Doluisio, J. T.; Billups, N. F.; Dittert, L. W.; Sugita, E. T.; Swintosky, J. V. Drug absorption I: An in situ rat gut technique yielding realistic absorption rates. J. Pharm. Sci. 1969, 58, 1196-1200.
46. Belland, R. J.; Morrison, S. G.; Ison, C.; Huang, W. M. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. 1994, 14, 371-380. (Pubitemid 24325813)
47. Bürli, R. W.; Ge, Y.; White, S.; Baird, E. E.; Touami, S. M.; Taylor, M.; Kaizerman, J. A.; Moser, H. E. DNA binding ligands with excellent antibiotic potency against drug-resistant Gram-positive bacteria. Bioorg. Med. Chem. Lett. 2002, 12, 2591-2594. (Pubitemid 35245288)
48. Kaizerman, J. A.; Gross, M. I.; Ge, Y.; White, S.; Hu, W.; Duan, J. X.; Baird, E. E.; Johnson, K. W.; Tanaka, R. D.; Moser, H. E.; Bürli, R. W. DNA binding ligands targeting drug-resistant bacteria: Structure, activity, and pharmacology. J. Med. Chem. 2003, 46, 3914-3929. (Pubitemid 37034140)
49. Khalaf, A. I.; Waigh, R. D.; Drummond, A. J.; Pringle, B.; McGroarty, I.; Skellern, G. G.; Suckling, C. J. Distamycin analogues with enhanced lipophilicity: Synthesis and antimicrobial activity. J. Med. Chem. 2004, 47, 2133-2156. (Pubitemid 38453928)
50. Hu, W.; Bürli, R. W.; Kaizerman, J. A.; Johnson, K. W.; Gross, M. I.; Iwamoto, M.; Jones, P.; Lofland, D.; Difuntorum, S.; Chen, H.; Bozdogan, B.; Appelbaum, P. C.; Moser, H. E.DNAbinding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus. J. Med. Chem. 2004, 47, 4352-4355. (Pubitemid 39096824)
51. Grossman, T. H.; Bartels, D. J.; Mullin, S.; Gross, C. H.; Parsons, J. D.; Liao, Y.; Grillot, A.-L.; Stamos, D.; Olson, E. R.; Charifson, P. S.; Mani, N. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob. Agents Chemother. 2007, 51, 657-666. (Pubitemid 46185287)
52. Anthony, N. G.; Breen, D.; Clarke, J.; Donoghue, G.; Drummond, A. J.; Ellis, E. M.;Gemmell, C.G.;Helebeux, J. J.;Hunter, I. S.; Khalaf, A. I.; Mackay, S. P.; Parkinson, J. A.; Suckling, C. J.; Waigh, R. D. Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups. J. Med. Chem. 2007, 50, 6116-6125.
53. Piddock, L. J. V.; Jin, Y. F.; Griggs, D. J. Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J. Antimicrob. Chemother. 2001, 47, 261-270. (Pubitemid 32229567)
54. Hooper, D. C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 2000, 31 (Suppl. 2), S24-28. (Pubitemid 32269605)
55. O'Shea, R.; Moser, H. E. Physicochemical properties of antibacterial compounds: Implifications for drug discovery. J. Med. Chem. 2008, 51, 2871-2878. (Pubitemid 351706014)
56. Bryan, L. E.; Bedard, J. Impemeability to quinolones in Grampositive and Gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 1991, 10, 232-239.
57. Walle, T. Absorption and metabolism of flavonoids. Free Radical Biol. Med. 2004, 36, 829-837. (Pubitemid 38401062)
58. Krolicka, A.; Szpitter, A.; Gilgenast, E.; Romanik, G.; Kaminski, M.; Lojkowska, E. Stimulation of antibacterial naphthoquinones and flavonoids accumulation in carnivorous plants grown in vitro by addition of elicitors. Enzyme Microb. Technol. 2008, 42, 216-221.
59. Biasutto, L.; Marotta, E.; De March, U.; Zoratti, M.; Paradisi, C. Ester based precursors to increase the bioavailability of quercetin. J. Med. Chem. 2007, 50, 241-253. (Pubitemid 46147705)
60. Hallett, P.; Grimshaw, A. J.; Wigley, D. B.; Maxwell, A. Cloning of the DNA gyrase genes under tac promoter control: Overproduction of the gyrase A and B proteins. Gene 1990, 93, 139-142. (Pubitemid 20353095)
61. Peng, H.; Marians, K. J. Overexpression and purification of bacterial topoisomerase IV. Methods Mol. Biol. 1999, 94, 163-169.